Skip to main content

Table 1 Key information of the DELIVER trial

From: CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

DELIVER [28]

Class & Cardiovascular (CV) outcomes

HR (95% CI)

p-value

Primary composite outcome

Composite of worsening heart failure (HF) (defined as unplanned hospitalization for HF or an urgent visit for HF or CV death)

0.82 (0.73–0.92)

 < 0.001

Primary outcome

CV death

0.88 (0.74–1.05)

 

Secondary outcome

Total number of worsening HF events and CV deaths

0.77 (0.67–0.89)

 < 0.001

Secondary outcome

Change in KCCQa total symptom score at month 8

1.11 (1.03–1.21)

 < 0.009

Secondary outcome

Mean change in KCCQa total symptom score at month 8 among survivors

2.4 (1.5–3.4)

 

Secondary outcome

Death from any cause

0.94 (0.83–1.07)

 

Adverse events

Event rate (%) active vs. placebo group

 

Any serious adverse events (death included)

43.5 vs. 45.5

 
  1. aThe Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item self-administered questionnaire developed to independently measure the participant’s perception of their health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL) within a 2 week recall period
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840